List of Ongoing Clinical Trials: Patient Summary

GOG-0218
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo vs Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo, vs Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Stage III (Suboptimal), and All Stage IV Epithelial Ovarian and Primary Peritoneal Cancer

Summary

Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether carboplatin, paclitaxel, and bevacizumab are more effective than carboplatin, paclitaxel, and placebo in treating ovarian epithelial or primary peritoneal cancer.

This randomized phase III trial is studying carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients with stage III or stage IV ovarian epithelial or primary peritoneal cancer.

Consent Form for Patients | Fast Fact Sheet